{"task_id": "82f4162011e1da03", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 167/464)", "text": "\nSPECIFIC ENTITIES (CONT\u2019D)\nBleeding Diathesis\n155\n\n--- Page 177 ---\nHypercoagulable States\nDIFFERENTIAL DIAGNOSIS\nANTICOAGULATION FACTORS\n\u0002\nDEFICIENCY\nprotein S, protein C, antithrombin\nIII, plasminogen. Secondary causes of clotting\nfactor deficiencies include HITT, DIC, TTP, HUS,\nPNH, APA, and nephrotic syndrome (reduced\nprotein S and protein C)\n\u0002\nALTERATION\nfactor V Leiden, prothrombin G20210A\n\u0002\nEXCESS\nfibrinogen, hyperhomocysteinemia\nVASCULAR\nDAMAGE\nvasculitis,\nsepsis,\ntrauma, surgery, cancer (Trousseau\u2019s syndrome,\nlymphoproliferative disease)\nSTASIS\nbed rest, pregnancy, air travel, leg cast\nPATHOPHYSIOLOGY\nRISK FACTORS FOR VENOUS THROMBOEMBOLISM\n\u0002\nCOAGULATION FACTORS\nexcess, mutation (factor V\nLeiden, prothrombin), deficiency (protein S, pro\ntein C, antithrombin III, plasminogen, tissue plas\nminogen activator)\n\u0002\nNEOPLASTIC\nsolid tumors, myeloproliferative\n\u0002\nOTHERS\nimmobilization,\nsurgery,\ncongestive\nheart failure, oral contraceptives, hormone repla\ncement therapy, pregnancy, nephrotic syndrome\nRISK FACTORS FOR ARTERIAL\nTHROMBOEMBOLISM\n\u0002\nATHEROSCLEROSIS\nhypertension, diabetes, smoking\n\u0002\nEMBOLIC\nAF, atrial myxoma, endocarditis, choles\nterol emboli, MI with ventricular thrombosis, para\ndoxical embolism\n\u0002\nOTHERS\nSLE\nRISK FACTORS FOR ARTERIAL AND VENOUS\nTHROMBOEMBOLISM\n\u0002\nFACTORS\nhomocysteinemia,\ndysfibrinogenemia,\nplasminogen activator deficiency\n\u0002\nPLATELET\nDEFECTS\nmyeloproliferative disorders,\nHITT, PNH\n\u0002\nHYPERVISCOSITY\npolycythemia rubra vera, Wal\ndenstrom\u2019s macroglobulinemia, cryoglobulinemia,\nsickle cell disease\n\u0002\nOTHERS\nantiphospholipid\nantibody\nsyndrome,\nvasculitis, paradoxical embolism\n\u0002\nBIOPROSTHETIC HEART VALVE\nlow level anticoagu\nlation (INR 2 3) in first 3 months following valve\nreplacement\nNEJM 2002 346:10\nFACTOR V LEIDEN\nmutation that resists cleavage\nby activated protein C. Most common hereditary form\nof thrombophilia (3 4% general population)\nTHROMBOPHILIC MUTATIONS\nantithrombin III,\nhomozygous factor V Leiden >protein S, protein C >\nheterozygous factor V Leiden in terms of risk of clots\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, PT, INR, activated protein C resis\ntance, factor V Leiden, prothrombin G20210A,\nanticardiolipin antibody, lupus anticoagulant,\nhomocysteine, protein C, protein S, antithrombin\nIII, fibrinogen, urinalysis\n\u0002\nIMAGING\nCXR\nSPECIAL\n\u0002\nPREGNANCY TEST\nif female <50\nRelated Topics\nAnticoagulation Therapy (p. 160)\nDVT (p. 158)\nPulmonary Embolism (p. 8)\nDIAGNOSTIC ISSUES\nWARFARIN AND PROTEIN C\ndraw protein C and S\nprior to warfarin therapy as it reduces protein C\nbefore those of all other vitamin K dependent factors\nMANAGEMENT\nACUTE\nABC, O2 to keep sat >94%, IV, consider\nthrombolysis\nANTICOAGULATION\nheparin\n(unfractionated\nheparin 5000U IV bolus, then 1000U/h and adjust to\n1.5 2.5\u0003 normal PTT) or LMWH (enoxaparin 1 mg/kg\nSC BID or 1.5 mg/kg SC daily). Start warfarin 5 mg PO\ndaily within 72 h and continue heparin/LMWH until\nINR is between 2 and 3 for two consecutive days\nIVC FILTER\nif anticoagulation contraindicated\nTREATMENT ISSUES\nWARFARIN USE AND PROTEIN C DEFICIENCY\npatients with protein C deficiency given warfarin\nmay be susceptible to transient hypercoagulable\nstate (coumadin necrosis). This can be avoided by\nadministering heparin along with warfarin\nPRIMARY PROPHYLAXIS OF THROMBOEMBOLISM\nIN HOSPITALIZED MEDICAL PATIENTS\n\u0002\nINDICATIONS\npatients on the medical service >40\nyear old have limited mobility for \u00063 days, and\nhave at least 1 of following risk factors\n\u0002\nCONDITIONS\nacute infectious disease, conges\ntive heart failure, acute myocardial infarction,\nacute respiratory disease, stroke, rheumatic dis\nease, inflammatory bowel disease, cancer\n\u0002\nCLINICAL\nCHARACTERISTIC\nprevious\nvenous\nthromboembolism, older age (especially >75),\n156\nHypercoagulable States", "text_length": 3744, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 167/464)", "type": "chunk", "chunk_index": 166, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.475549", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.476358", "status": "complete", "chunks_added": 2}